Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan

Takashi Kadowaki, Masakazu Haneda, Hiroshi Ito, Kazuyo Sasaki, Yuka Yamada

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


Introduction: Teneligliptin, a dipeptidyl peptidase 4 inhibitor, was approved for the treatment of type 2 diabetes mellitus (T2DM) in Japan in 2012. However, clinical trials of teneligliptin involved limited numbers of elderly patients. Therefore, we investigated the safety and efficacy of teneligliptin in elderly patients with T2DM. Methods: This 3-year follow-up RUBY surveillance registered patients with T2DM who started treatment with teneligliptin between May 2013 and February 2015 in Japan. Collected data included demographics, treatments, adverse drug reactions (ADRs), and laboratory variables. Data were analysed for patients in three age subgroups (< 65, ≥ 65 to < 75, or ≥ 75 years old). Safety was assessed as the incidence of ADRs and efficacy was assessed in terms of glycaemic control, for up to 3 years. Results: The ADRs and serious ADRs occurred in 3.35% and 0.65% of 4596 patients aged < 65 years, in 4.42% and 1.22% of 3371 patients aged ≥ 65 to < 75 years, and in 3.99% and 1.69% of 2729 patients aged ≥ 75 years. The most common ADRs in patients aged ≥ 65 to < 75 years and ≥ 75 years were gastrointestinal disorders, but the incidence of these ADRs did not show an age-dependent increase. Hypoglycaemia occurred in 0.24%, 0.56%, and 0.29% of patients in each age subgroup, respectively. The least-squares mean changes in glycosylated haemoglobin (HbA1c) adjusted for baseline were − 0.66 ± 0.02% (n = 2177), − 0.72 ± 0.02% (n = 1689), and − 0.77 ± 0.03% (n = 1161) at 3 years. Conclusion: There was no clear difference in the number of ADRs among the three age subgroups, although the incidence of serious ADRs was higher in elderly patients than in patients aged < 65 years. We found no additional safety or efficacy concerns among elderly patients beyond those already described in the package insert. The present results support the use of teneligliptin in elderly patients with T2DM in real-world clinical practice. Trial Registration: Japic Clinical Trials Information identifier, Japic CTI-153047.

Original languageEnglish
Pages (from-to)2477-2492
Number of pages16
JournalAdvances in Therapy
Issue number5
Publication statusPublished - May 1 2020


  • Diabetes
  • Dipeptidyl peptidase 4 inhibitor
  • Elderly patients
  • Post-marketing surveillance
  • Real-world
  • Teneligliptin
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan'. Together they form a unique fingerprint.

Cite this